Key Points
- CFO Adam Laponis sold 2,597 shares on April 9 at an average price of $49.89 for $129,564, and the sale was disclosed in an SEC filing as being made to cover tax withholding on vested equity awards.
- The April sale continues a recent pattern of insider sales (7,000 shares on Feb 12 at $50 and 3,000 shares on Jan 13 at $40) and leaves Laponis with 125,694 shares, a 2.02% reduction in his position.
- Twist’s stock has climbed about 5.2% recently; the company reported Q4 EPS of ($0.50) that missed estimates while revenue of $103.7M beat consensus and was up 16.9% year-over-year, and analysts hold a consensus rating of “Moderate Buy” with an average price target of $46.50.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,597 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $49.89, for a total transaction of $129,564.33. Following the transaction, the chief financial officer owned 125,694 shares in the company, valued at $6,270,873.66. This represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Adam Laponis also recently made the following trade(s):
- On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00.
- On Tuesday, January 13th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00.
Twist Bioscience Stock Up 5.2%
Twist Bioscience stock opened at $50.38 on Tuesday. The company has a market capitalization of $3.09 billion, a P/E ratio of -39.36 and a beta of 2.20. The firm's fifty day simple moving average is $47.85 and its 200-day simple moving average is $38.38. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $57.88.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business's quarterly revenue was up 16.9% on a year-over-year basis. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Institutional Trading of Twist Bioscience
Several institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. boosted its position in shares of Twist Bioscience by 28.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 14,970 shares of the company's stock valued at $475,000 after acquiring an additional 3,359 shares in the last quarter. Axxcess Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at about $201,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at about $242,000. Empowered Funds LLC acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at about $58,000. Finally, VARCOV Co. acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at about $263,000.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the stock. Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a report on Tuesday, February 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a report on Friday, March 27th. Guggenheim lifted their target price on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock a "buy" rating in a report on Monday, March 30th. Barclays lifted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, February 3rd. Finally, Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.50.
Read Our Latest Stock Report on TWST
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
